Skeletal muscle-based treatment strategies for immune checkpoint inhibitor

Skeletal muscle-based treatment strategies for immune checkpoint inhibitor - Skeletal muscle-based treatment strategies for immune checkpoint inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061297

Enrollment

Registered

2026-06-01

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients starting treatment with immune checkpoint inhibitors Patients diagnosed with urothelial carcinoma Patients who have provided informed consent to participate in this study by signing a consent form Patients aged 18 years or older

Exclusion criteria

Exclusion criteria: Individuals from whom written consent could not be obtained Other patients deemed unsuitable by the attending physician

Design outcomes

Primary

Measure	Time frame
The relationship between body composition associated with sarcopenia and serum concentrations of skeletal muscle-related factors	—

Secondary

Measure	Time frame
The relationship between body composition associated with sarcopenia and immune status and immune function The relationship between body composition associated with sarcopenia and treatment outcomes The relationship between blood-based immune status and treatment outcomes The relationship between skeletal muscle-related factors and treatment outcomes The relationship between blood concentrations of skeletal muscle-related factors and immune status The effects of serum from sarcopenia patients and skeletal muscle-related factors on immune cells Treatment outcomes include treatment completion rate, duration of treatment, adverse events, overall survival, progression-free survival, best response, reasons for treatment discontinuation, occurrence of unscheduled visits, occurrence of unscheduled hospitalizations, relative dose intensity, and changes in quality of life (QOL).	—

Measure

Time frame

The relationship between body composition associated with sarcopenia and immune status and immune function The relationship between body composition associated with sarcopenia and treatment outcomes The relationship between blood-based immune status and treatment outcomes The relationship between skeletal muscle-related factors and treatment outcomes The relationship between blood concentrations of skeletal muscle-related factors and immune status The effects of serum from sarcopenia patients and skeletal muscle-related factors on immune cells Treatment outcomes include treatment completion rate, duration of treatment, adverse events, overall survival, progression-free survival, best response, reasons for treatment discontinuation, occurrence of unscheduled visits, occurrence of unscheduled hospitalizations, relative dose intensity, and changes in quality of life (QOL).

—

Countries

Japan

Contacts

Public ContactSumika Osa

Hamamatsu University School of Medicine, University Hospital Department of hospital pharmacy

osa.su@hama-med.ac.jp0534352767

Outcome results